ArriVent BioPharma/$AVBP

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About ArriVent BioPharma

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

Ticker

$AVBP
Sector
Health Care
Primary listing
NASDAQ

Industry

Biotechnology
Headquarters
Newtown Square, United States

Employees

52

ISIN

US04272N1028
Website
arrivent.com

AVBP Metrics

BasicAdvanced
$779M
-
-$3.78
-
-

What the Analysts think about AVBP

Analyst ratings (Buy, Hold, Sell) for ArriVent BioPharma stock.

Bulls say / Bears say

ArriVent BioPharma's lead candidate, firmonertinib, demonstrated a median progression-free survival of 16.0 months in first-line NSCLC patients with EGFR PACC mutations, indicating strong efficacy. (globenewswire.com)
The company successfully completed a $75 million public offering in July 2025, bolstering its financial position to support ongoing and future clinical programs. (globenewswire.com)
Analysts have a consensus 'Strong Buy' rating for AVBP, with a 12-month price target of $39.00, suggesting significant upside potential. (stockanalysis.com)
ArriVent reported a net loss of $64.4 million for Q1 2025, reflecting high operational expenses and ongoing financial challenges. (marketchameleon.com)
The company's stock price has experienced volatility, with a 52-week range between $15.47 and $36.37, indicating potential instability. (stockanalysis.com)
Despite positive clinical data, firmonertinib is still in clinical trials, and any delays or unfavorable results could negatively impact the company's prospects. (globenewswire.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.

AVBP Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

AVBP Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

AVBP News

AllArticlesVideos
Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Benzinga·1 week ago
ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewsWire·1 week ago
ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants

ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AVBP

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs